Evidence map›Paper›PMID 22464315›Full record

ArticleEJNMMI research2012

High resolution tumor targeting in living mice by means of multispectral optoacoustic tomography.

Andreas Buehler, Eva Herzog, Angelica Ale, Bradley D Smith, Vasilis Ntziachristos, Daniel Razansky

Abstract read
In one paragraph

Article in EJNMMI research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Assessment of Breast Tumors Using Multispectral Optoacoustic Tomography in a Surgical Setting.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Targeting Acidity in Pancreatic Adenocarcinoma: Multispectral Optoacoustic Tomography Detects pH-Low Insertion Peptide Probes In Vivo.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Andreas BuehlerInstitute for Biological and Medical Imaging, Technische Universität München und Helmholtz Zentrum München, Ingoldstädter Landstraße 1, Neuherberg 85764, Germany. dr@tum.de.
Eva Herzog
Angelica Ale
Bradley D Smith
Vasilis Ntziachristos
Daniel Razansky

Funding

PROMOTERS AND INHIBITORS OF MEMBRANE FUSIONR01GM059078 · NIGMS · UNIVERSITY OF NOTRE DAME · PI SMITH, BRADLEY D · 1999 to 2019
$5.8M
NIGMS NIH HHS R01 GM059078
6 · The paper itself

Abstract

backgroundTumor targeting is of high clinical and biological relevance, and major efforts have been made to develop molecular imaging technologies for visualization of the disease markers in tissue. Of particular interest is apoptosis which has a profound role within tumor development and has significant effect on cancer malignancy.

methodsHerein, we report on targeting of phosphatidylserine-exposing cells within live tumor allograft models using a synthetic near infrared zinc(II)-dipicolylamine probe. Visualization of the probe biodistribution is performed with whole body multispectral optoacoustic tomography (MSOT) system and subsequently compared to results attained by planar and tomographic fluorescence imaging systems.

resultsCompared to whole body optical visualization methods, MSOT attains remarkably better imaging capacity by delivering high-resolution scans of both disease morphology and molecular function in real time. Enhanced resolution of MSOT clearly showed that the probe mainly localizes in the vessels surrounding the tumor, suggesting that its tumor selectivity is gained by targeting the phosphatidylserine exposed on the surface of tumor vessels.

conclusionsThe current study demonstrates the high potential of MSOT to broadly impact the fields of tumor diagnostics and preclinical drug development.

Identifiers

PMID22464315
PMCPMC3337810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.